EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings

Neerja Bhatla, MaryLuz Rol iD, Seema Singhal, Showket Hussain, Anushree Patil, Pranay Tanwar, Shalini Singh, Vikrant M Bhor, Kiran Munne iD, Richa Vashishtha, Shachi Vashist, Eric Lucas und 17 weitere

International Journal of Cancer · 15.10.2026 · 159 (8) · 2004-2014

DOI: 10.1002/ijc.70534 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Cancer, online erschienen am 07.06.2026. Verfasst von Neerja Bhatla und 28 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, Human Papillomavirus Viruses. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Research Foundation-Flanders (FWO), Belgium, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent infection with high‐risk human papillomavirus (HR‐HPV) is the necessary cause of cervical cancer, with approximately 95% of cases attributable to eight most carcinogenic HPV types (16/18/31/33/35/45/52/58). Several HPV assays have recently been developed in India for use in cervical cancer screening, including reduced‐valency tests targeting seven/eight oncogenic HPV types. We evaluated the clinical accuracy and reproducibility of four such assays: PathoDetect‐HPV‐14, HPV‐Q (14 types), Truenat‐HR‐HPV‐Plus (8 types), and PathoDetect‐HPV‐7 (7 types). Using the VALGENT framework, 1159 cervical samples from the ESTAMPA study conducted in Argentina and Costa Rica were analysed with the new assays. The samples included 97 cases of CIN2+ (19 CIN2, 72 CIN3, and 6 cancers). Assay performance was compared in a blinded manner with established reference tests (Cobas‐4800 and Allplex‐HPV‐HR) and reduced‐valency comparators. Sensitivity, specificity, agreement, and repeatability were assessed. Truenat‐HR‐HPV‐Plus demonstrated a sensitivity of 80.4% (95% CI: 71.1–87.8) and specificity of 91.5% (95% CI: 89.5–93.2) for CIN2+. It met IARC validation criteria and showed non‐inferior performance to Allplex‐HPV‐HR‐8, with relative sensitivity of 1.03 (95% CI: 0.96–1.09) for CIN2+ and 1.00 (95% CI: 0.96–1.04) for CIN3+, and relative specificity of 0.99 (95% CI: 0.97–1.00) and 0.98 (95% CI: 0.97–1.00), respectively. Repeatability was 93.3% (κ = 0.79). PathoDetect‐HPV‐7 showed lower sensitivity (68.1%) with specificity of 89.0%. HPV‐Q and PathoDetect‐HPV‐14 did not meet validation criteria. This study represents the first formal validation of reduced‐valency HPV assays and demonstrates that Truenat‐HR‐HPV‐Plus provides robust clinical performance with higher specificity than 14‐valent assays, supporting its potential to improve screening efficiency and reduce unnecessary referrals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsEarly Detection of CancerHuman Papillomavirus VirusesUterine Cervical DysplasiaPapillomaviridaeHumansFemaleReproducibility of ResultsSensitivity and SpecificityCosta RicaResource-Limited SettingsMiddle AgedArgentinaAdultDNA, ViralRapid Diagnostic Tests

Stichwörter der Autor:innen

cervical cancer screeningclinical validationhigh‐risk HPV assayslow‐resource settings

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • All India Institute of Medical Sciences, New Delhi, India.
  • Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France.
  • ICMR-National Institute of Cancer Prevention and Research, Noida, India.
  • ICMR-National Institute for Research on Women's Health (ICMR-NIRWoH), Formerly ICMR-NIRRCH, Mumbai, India.
  • Biotechnology Industry Research Assistance Council, Department of Biotechnology, New Delhi, India.
  • Instituto Nacional de Enfermedades Infecciosas - ANLIS Malbrán, Buenos Aires, Argentina.

ORCID-Profile: MaryLuz Rol, Kiran Munne, Gary M Clifford, Partha Basu

Förderung

  • World Health Organization
  • Research Foundation-Flanders (FWO), Belgium
  • Gates Foundation
  • Bill and Melinda Gates Foundation
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Bhatla, N., Rol, M., Singhal, S., Hussain, S., Patil, A., Tanwar, P., Singh, S., Bhor, V. M., Munne, K., Vashishtha, R., Vashist, S., Lucas, E., Muwonge, R., Ramírez, A. T., Singh, A., Khan, V., Rani, J., Firdausi, N., Sisodiya, S., …, & Basu, P. (2026). Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings. International Journal of Cancer, 159(8), 2004-2014. https://doi.org/10.1002/ijc.70534

Vancouver

Bhatla N, Rol M, Singhal S, Hussain S, Patil A, Tanwar P, et al. Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings. International Journal of Cancer. 2026;159(8):2004-2014. doi:10.1002/ijc.70534

BibTeX
@article{Bhatla2026,
  author = {Bhatla, Neerja and Rol, MaryLuz and Singhal, Seema and Hussain, Showket and Patil, Anushree and Tanwar, Pranay and Singh, Shalini and Bhor, Vikrant M and Munne, Kiran and Vashishtha, Richa and Vashist, Shachi and Lucas, Eric and Muwonge, Richard and Ramírez, Arianis Tatiana and Singh, Anju and Khan, Vikas and Rani, Jyoti and Firdausi, Nasera and Sisodiya, Sandeep and Wakchaure, Rutuja and Picconi, María Alejandra and Calderón, Alejandro and Bell, Margo and De Smet, Annemie and Vorsters, Alex and Clifford, Gary M and Chandra, Madhavi and Kumar, Jitendra and Basu, Partha},
  title = {Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {2004--2014},
  doi = {10.1002/ijc.70534}
}
Kostenlos starten →